Fortress Biotech IncNASDAQ:FBIO
- LAST PRICE1.7200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.6800/ 1
- Ask / Lots1.7200/ 2
- Open / Previous Close1.7100 / 1.7200
- Day Range
- 52 Week Range
- Volume104,621
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FBIO |
|---|---|---|
| 09:32 ET | 2334 | 1.766 |
| 09:34 ET | 200 | 1.72 |
| 09:39 ET | 300 | 1.72 |
| 09:43 ET | 1200 | 1.73 |
| 09:45 ET | 343 | 1.74 |
| 09:48 ET | 601 | 1.75 |
| 09:50 ET | 100 | 1.73 |
| 09:52 ET | 100 | 1.73 |
| 10:01 ET | 300 | 1.75 |
| 10:03 ET | 400 | 1.76 |
| 10:06 ET | 1630 | 1.78 |
| 10:08 ET | 2404 | 1.773 |
| 10:10 ET | 100 | 1.76 |
| 10:14 ET | 795 | 1.7646 |
| 10:15 ET | 100 | 1.76 |
| 10:30 ET | 200 | 1.7536 |
| 10:39 ET | 300 | 1.74 |
| 10:44 ET | 300 | 1.74 |
| 10:50 ET | 396 | 1.73 |
| 10:57 ET | 1000 | 1.74 |
| 11:08 ET | 3476 | 1.72 |
| 11:09 ET | 300 | 1.72 |
| 11:24 ET | 500 | 1.7272 |
| 11:26 ET | 1712 | 1.73 |
| 11:38 ET | 100 | 1.73 |
| 12:02 ET | 101 | 1.73 |
| 12:07 ET | 3205 | 1.72 |
| 12:09 ET | 100 | 1.72 |
| 12:16 ET | 690 | 1.72 |
| 12:18 ET | 100 | 1.72 |
| 12:30 ET | 100 | 1.73 |
| 12:39 ET | 200 | 1.72 |
| 12:41 ET | 200 | 1.7202 |
| 12:48 ET | 1250 | 1.72 |
| 12:50 ET | 100 | 1.72 |
| 01:01 ET | 400 | 1.73 |
| 01:06 ET | 1000 | 1.73 |
| 01:10 ET | 100 | 1.72 |
| 01:17 ET | 126 | 1.74 |
| 01:21 ET | 700 | 1.73 |
| 01:24 ET | 287 | 1.7381 |
| 01:28 ET | 3281 | 1.73 |
| 01:32 ET | 18968 | 1.71 |
| 01:35 ET | 1100 | 1.71 |
| 01:37 ET | 1000 | 1.72 |
| 01:55 ET | 2325 | 1.7251 |
| 01:57 ET | 300 | 1.72 |
| 02:04 ET | 8182 | 1.7 |
| 02:06 ET | 1100 | 1.72 |
| 02:33 ET | 250 | 1.715 |
| 02:40 ET | 300 | 1.71 |
| 02:54 ET | 1700 | 1.72 |
| 02:56 ET | 1556 | 1.715 |
| 02:58 ET | 100 | 1.72 |
| 03:03 ET | 300 | 1.72 |
| 03:18 ET | 285 | 1.72 |
| 03:21 ET | 1000 | 1.725 |
| 03:23 ET | 1466 | 1.73 |
| 03:25 ET | 650 | 1.73 |
| 03:27 ET | 100 | 1.73 |
| 03:30 ET | 200 | 1.73 |
| 03:43 ET | 100 | 1.725 |
| 03:45 ET | 854 | 1.72 |
| 03:50 ET | 300 | 1.72 |
| 03:56 ET | 100 | 1.71 |
| 03:57 ET | 1100 | 1.724 |
| 03:59 ET | 14109 | 1.72 |
Apr 25, 2024
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024, from 8:30AM ET on Thursday Apr 25, 2024 by Dow Jones
8:30AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 24, 2024
Avenue Therapeutics Announces Reverse Stock Split, from 7:30AM ET on Wednesday Apr 24, 2024 by Dow Jones
7:30AM ET on Wednesday Apr 24, 2024 by Dow Jones
Mar 28, 2024
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights, from 4:05PM ET on Thursday Mar 28, 2024 by Dow Jones
4:05PM ET on Thursday Mar 28, 2024 by Dow JonesPress Release: Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights, from 4:05PM ET on Thursday Mar 28, 2024 by Dow Jones
4:05PM ET on Thursday Mar 28, 2024 by Dow JonesMustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases, from 9:00AM ET on Thursday Mar 28, 2024 by Dow Jones
9:00AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Fortress Biotech Inc | 33.1M | -0.2x | --- |
Cannabis Bioscience International Holdings Inc | 6.3M | 0.0x | --- |
Wuhan General Group (China) Inc | 60.0 | 0.0x | --- |
Personalis Inc | 64.0M | -0.6x | --- |
MDxHealth SA | 67.4M | 0.0x | --- |
Cidara Therapeutics Inc | 59.3M | -50.0x | --- |
Company Information
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).
Contact Information
- Headquarters
- 1111 KANE CONCOURSE, SUITE 301BAY HARBOR ISLANDS, FL, United States 33154
- Phone
- 781-652-4500
- Fax
- 781-652-4545
Executives
- Executive Chairman of the Board, President, Chief Executive Officer
- Lindsay Rosenwald
- Chief Financial Officer, Corporate Secretary
- David Jin
- Executive Vice Chairman - Strategic Development, Director
- Michael Weiss
- Senior Vice President - Biologics Operations
- George Avgerinos
- Independent Director
- Jimmie Harvey
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $33.1M |
|---|---|
Revenue (TTM) | $84.5M |
Shares Outstanding | 19.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-8.88 |
Book Value | $1.49 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 0.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -172.41% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
